Last reviewed · How we verify
Lisata Therapeutics, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
4 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Auto-CD34+ cells | Auto-CD34+ cells | phase 3 | Cell therapy | Regenerative Medicine / Cardiovascular |
Therapeutic area mix
- Cardiovascular · 2
- Regenerative Medicine / Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Biosolution Co., Ltd. · 1 shared drug class
- Bone Therapeutics S.A · 1 shared drug class
- Brainstorm-Cell Therapeutics · 1 shared drug class
- Celavie Bioscences, LLC · 1 shared drug class
- China Spinal Cord Injury Network · 1 shared drug class
- City of Hope Medical Center · 1 shared drug class
- Diakonos Oncology Corporation · 1 shared drug class
- Avicenna Research Institute · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Lisata Therapeutics, Inc.:
- Lisata Therapeutics, Inc. pipeline updates — RSS
- Lisata Therapeutics, Inc. pipeline updates — Atom
- Lisata Therapeutics, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Lisata Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lisata-therapeutics-inc. Accessed 2026-05-16.